FDA Issues Alert on Irbesartan Due to Contamination

Share this post

Testing confirmed the presence of the impurity NDEA in recalled lots of irbesartan from SciGen Pharmaceuticals and in the active substance supplied to the US market by Aurobindo Pharma.
News Alerts

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply